AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06490562
Drug: Non Cy
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of low-dose CNI (CSA 25mg Q12H or FK506 0.25mg Q12H combined with azole fungal drugs) for 2 weeks to prevent GVHD at 0 days after gDLI
Trial: NCT05812157
Drug: Anti-IL-17 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in both groups will be on anti-IL-17 therapy
Trial: NCT06636877
Drug: BR1019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone
Trial: NCT06636877
Drug: BR1019-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone
Trial: NCT06523673
Drug: second-line systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a second-line docetaxel/albumin-bound paclitaxel-based systemic therapy regimen
Trial: NCT06138327
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT01053702
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06068179
Drug: Mycophenolate Mofetil, Oral, 250 Mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycophenolate Mofetil, Oral, 500Mg twice daily for 12 months, combined with methimazole standard therapy
Trial: NCT05130970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a matching placebo IV loading dose, followed by 3 SC doses.
Trial: NCT05821309
Drug: PEG-3350 with electrolytes
RxNorm normalized name: PEG-3350 with Electrolytes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The purpose of this study is to determine if a sustained change in the fecal microbiome occurs after prolonged use of an antegrade continence enema bowel flush regimen. Patients' microbiomes will be evaluated via 16s rRNA sequencing. PEG 3350 will be compared to PEG 3350 with electrolytes
Trial: NCT05358821
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAGE-718-matching oral capsules
Trial: NCT05378061
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
Trial: NCT06433908
Drug: Salbutamol HFA-152a
RxNorm normalized name: HYDROFLUOROCARBON 152A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg (ex-valve), given at 20-second intervals.
Trial: NCT06126783
Drug: IBI311
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first dose was 10 mg/kg, followed by 7 maintenance doses of 20 mg/kg, Q3W
Trial: NCT05257902
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1T bid/day
Trial: NCT05095168
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT05578482
Drug: Elocon 0.1 % Topical Cream
RxNorm normalized name: Elocon 0.1 % Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups are treated with elocon for five days.
Trial: NCT05109702
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vehicle solution.
Trial: NCT05394103
Drug: Q901
RxNorm normalized name: Quinelorane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study drug Q901 will be administered by IV infusion over a 30-minute period using a QW dosing schedule for 4 weeks, followed by a Q2W interval dosing schedule thereafter
Trial: NCT04771676
Drug: Oncorine (H101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A modified human recombinant type 5 adenovirus with genetic modifications.
Trial: NCT06524596
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The group received 0.02 mg/kg normal saline intravenously over 5 minutes, 30 minutes before anaesthesia induction
Trial: NCT06524596
Drug: propofol and remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaesthesia was induced with 2 mg/kg propofol and 0.6 μg/kg remifentanil and maintained with a target-controlled infusion (TCI) of propofol and remifentanil, using the Marsh and Minto models, respectively.
Trial: NCT04984512
Drug: Mitizodone Phosphate tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitizodone Phosphate tablets will be administered with food.
Trial: NCT04984512
Drug: Placebo-matching tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered with food.
Trial: NCT06206902
Drug: After preconditioning with chemotherapy, F01 will be evaluated.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 300 mg/ m\^2 (D-5\~D-3)
Trial: NCT05035095
Drug: Placebo (semaglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo (semaglutide) once daily. Planned treatment duration will be 68 weeks.
Trial: NCT05279716
Drug: Eybelis ophthalmic solution 0.002%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic eye drop
Trial: NCT05660213
Drug: Huaier granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment period: Huaier Granule, oral administration, 10g each time, 3 times a day. Continuous medication until the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment. After disease progression, whether to continue the medication or not should be determined by the researcher and patient together.
Trial: NCT05448391
Drug: RIST4721
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
Trial: NCT05507645
Drug: standard medical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiplatelet or anticoagulant treatment at the discretion of local investigators.
Trial: NCT06386211
Drug: MAGNE-B6 Oral Solution
RxNorm normalized name: vitamin B6 Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution.
Trial: NCT06386211
Drug: MAGNE-B6 New Formulation Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New formulation tablet.
Trial: NCT04890106
Drug: Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the second arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm ± 2 hours for 42 days.
Trial: NCT02571608
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
Trial: NCT05446623
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The one in the OA group will be given a bolus of Sufentanil before and during the surgery.
Trial: NCT05595772
Drug: Drug: Growth Factors (CGF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of biological membrane of Concentrated growth factor (CGF) over bone grafting and implant
Trial: NCT05595772
Drug: Drug: Growth Factors (PRGF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of biological membrane of Plasma rich in growth factors combined with Xenogeneic bone grafting material around immediate implant
Trial: NCT06351891
Drug: 14-day bismuth quadruple regimen containing cefuroxime and tetracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day bismuth quadruple regimen containing cefuroxime and tetracycline:Tegoprazan 50mg bid, Bismuth potassium citrate capsules 0.6g bid,Cefuroxime tablets 500mg bid,Tetracycline 500mg tid,14 days.Evaluating the efficacy and safety of 14-Day bismuth quadruple therapy containing cefuroxime and tetracycline for Helicobacter pylori eradication.
Trial: NCT04859374
Drug: treatment as usual (TAU) (pharmacological)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any pharmacological therapy used for managing chronic pain or chronic migraine
Trial: NCT06648772
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream
Trial: NCT05795153
Drug: LOU064
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOU064 (Open-Label) taken orally for 12 weeks
Trial: NCT04599465
Drug: ELX/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination (FDC) tablets for oral administration.
Trial: NCT05464368
Drug: [18F]RO-948
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Johns Hopkins University has conducted the first in human study in collaboration with Roche for 18F-RO948and found that 18F-RO948isa promising radioligand for imaging tau pathology in AD, showing excellent brain uptake and displaying little off-target binding(22, 17, 34).The injected activity for18F-RO948will be as low as practicable, while still allowing accurate quantification of the PET images.The injected dose of 370MBq(10mCi)has been selected based on the radiation dose estimates for18F-RO948gathered in human subjects provided by Michael Stabin, Ph.D., and in accordance with the principle that radiation doses should be as low as reasonably achievable.~This radiotracer will be manufactured on site in the Mallinckrodt Institute of Radiology Cyclotron Facility, a certified Nuclear Pharmacy.
Trial: NCT04771143
Drug: AFQ056
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT04771143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo for oral administration
Trial: NCT04799353
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC)
Trial: NCT04799353
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV)
Trial: NCT05293626
Drug: NR082 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose is 1.5E9 vg, 0.05 mL eye/dose.~Dose Escalation:~If drug-related dose-limiting toxicity (DLT) events are observed in ≤ 2 of the 6 evaluable subjects using the starting dose within 6 weeks after the dosing of NR082, the dose can be escalated to 4.5E9 vg, 0.05 mL eye/dose (high dose) after approval by SRC.~Dose De-escalation： If drug-related dose-limiting toxicity (DLT) events are observed in \> 2 of the 6 evaluable subjects using the starting dose within 6 weeks after the dosing of NR082, the dose can be de-escalated to 0.5E9 vg, 0.05 mL eye/dose (low dose) after approval by SRC.~If drug-related dose-limiting toxicity (DLT) events are observed in \> 2 of the 6 evaluable subjects within 6 weeks after the dosing of NR082 at the high dose, the dose can be de-escalated to 3.0E9 vg, 0.05 mL eye/dose (intermediate dose) after the approval by SRC.
Trial: NCT06271928
Drug: Yijing Keli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once enrolled, participants will be administrated Yijing Keli
Trial: NCT05096494
Drug: SP-103
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP-103 topical system is worn daily for 12 hours per day for 28 days
Trial: NCT05096494
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo topical system is worn daily for 12 hours per day, for 28 days
Trial: NCT05397639
Drug: Masupirdine 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, Once Daily
Trial: NCT05397639
Drug: Masupirdine 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, Once Daily
Trial: NCT05397639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo Tablet, Once Daily
Trial: NCT06583369
Drug: Liangxue ointment（Traditional Chinese Ointment）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The main ingredients of Liangxue Ointment include: Lithospermum sibiricum, Sanguisorba Sanguis, Rehmannia glutinosa, Gardenia, rhubarb, skullcap, borneol, dragon's blood, olibanum and myrrh.~Apply 2 times a day, 14 days is a course of treatment, and the treatment is 2 courses.
Trial: NCT06583369
Drug: Urea cream
RxNorm normalized name: Amino Acid-Urea Cream
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply 2 times a day, 14 days is a course of treatment, and the treatment is 2 courses.
Trial: NCT04622813
Drug: nefopam, ketoprofen, paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive Nefopam and Ketoprofen in addition to the paracetamol intraoperatively prior to the anticipated end of the surgery
Trial: NCT04622813
Drug: saline infusion, ketoprofen, paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive one placebo infusion (saline infusion) in addition to the ketoprofen and paracetamol intraoperatively prior to the anticipated end of the surgery
Trial: NCT05512013
Drug: Ibuprofen 800 mg
RxNorm normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen taken orally 2 hours prior to exercise
Trial: NCT05512013
Drug: Celecoxib 200mg
RxNorm normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celebrex taken orally 2 hours prior to exercise
Trial: NCT05512013
Drug: Flurbiprofen 100 mg
RxNorm normalized name: flurbiprofen 100 MG
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen taken orally 2 hours prior to exercise
Trial: NCT05512013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert placebo taken orally 2 hours prior to exercise
Trial: NCT06195189
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed +platinum
Trial: NCT05271331
Drug: Wound infiltration with local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded injection of local anestetic (ropivacaine 0.35%, 40ml) in the skin, subcutaneous tissue and muscles at the site of surgical incision.
Trial: NCT05036967
Drug: HF medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment initiation patterns of patients with Heart Failure (HF) in an outpatient setting from Colombia.
Trial: NCT04620746
Drug: Penicillin Major Determinant (PrePen) Skin Testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin testing followed by oral challenge with amoxicillin 250 mg single dose
Trial: NCT04620746
Drug: Direct Oral challenge
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral challenge with test dose of amoxicillin 25mg followed by amoxicillin 250mg single dose
Trial: NCT06003088
Drug: HSK7653(5mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.
Trial: NCT06003088
Drug: HSK7653(25mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.
Trial: NCT05553184
Drug: Nicotinic Acid 50 MG Oral Tablet
RxNorm normalized name: Nicotinic acid 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a total dose of 1050 MG will be ingested. From time 0 to 180 minutes, doses of 150 MG will be repeated every 30 minutes.
Trial: NCT05278832
Drug: QLS31905
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QLS31905 injection
Trial: NCT04849715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo will be administered orally once daily
Trial: NCT05387668
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as a tablet.
Trial: NCT05480475
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On Day 3 (Treatment A2) and on Day 11 (Treatment C2) a single oral dose of 10 mg rosuvastatin will be administered under fasted conditions.
Trial: NCT04251819
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Trial: NCT06545097
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 2 days
Trial: NCT02866565
Drug: adipose-derived regenerative cells (ADRCs)
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of the experimental treatment
Trial: NCT06185764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for intravenous administration.
Trial: NCT04365660
Drug: 18-F FTC 146
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotracer, 10 mCi at pre- and post- chemotherapy, intravenous administration
Trial: NCT06078904
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, one pill a day, oral intake
Trial: NCT05483504
Drug: F61 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colorless or slightly yellow liquid, may be slightly opalescent
Trial: NCT05483504
Drug: F61 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colorless or slightly yellow liquid, may be slightly opalescent
Trial: NCT06669169
Drug: Jia Shen Tablet Placebo
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jia Shen Tablet Placebo contains 4 placebo tablets (0.47 g per placebo tablet),take orally, 2 times a day for 12 weeks
Trial: NCT05165992
Drug: Nebulized Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administration of nebulized Fentanyl (25 μg in 5 ml of normal saline) over 15 mins, thrice daily using a traditional nebulizer. Treatment duration - 48 hours
Trial: NCT06487455
Drug: SPH7485
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPH7485： Orally, once daily, 50-400mg, 21 days per cycle
Trial: NCT00000947
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05733078
Drug: Oral Rehydration Salt Formulations
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in control group will have a oral rehydration effervescent tablet to take with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The control group will then be provided vitamin C (intervention) effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks to see if there is any difference on biochemical testing or clinical scores.
Trial: NCT04600921
Drug: Placebo 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will receive Placebo 5mg orally daily for 52 weeks.
Trial: NCT04994080
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo QD or TIW
Trial: NCT04373785
Drug: NG101m
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral NG101m capsule continuously twice daily.
Trial: NCT04989959
Drug: [18F]PT2385
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]PT2385 infusion
Trial: NCT04049630
Drug: LEV 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
Trial: NCT04049630
Drug: LEV 1,5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
Trial: NCT04049630
Drug: LEV 2,5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
Trial: NCT04049630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 tablets of placebo will be administrated to the participants.
Trial: NCT05414591
Drug: DWP16001 drug A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet, Oral, once daily single dose
Trial: NCT05414591
Drug: DWP16001 drug B
RxNorm normalized name: INVESTIGATIONAL ANTI-VIRAL DRUGS HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablet, Oral, once daily single dose
Trial: NCT05703854
Drug: CAR.70/IL15-transduced CB-derived NK cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT05703854
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV (vein)
Trial: NCT06462508
Drug: [18F]F-PSMA-N5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject receive a single intravenous injection of \[18F\]F-PSMA-N5, and undergo PET/CT imaging within the specificed time.
Trial: NCT06462508
Drug: [68Ga]Ga-PSMA-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject receive a single intravenous injection of \[68Ga\]Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
Trial: NCT06304818
Drug: SCTB14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCTB14,IV